Abeona Therapeutics Incorporated (NASDAQ:ABEO) had a decrease of 12.5% in short interest. ABEO’s SI was 6.64M shares in January as released by FINRA. Its down 12.5% from 7.59M shares previously. With 735,800 avg volume, 9 days are for Abeona Therapeutics Incorporated (NASDAQ:ABEO)’s short sellers to cover ABEO’s short positions. The SI to Abeona Therapeutics Incorporated’s float is 30.83%. The stock increased 0.34% or $0.05 during the last trading session, reaching $14.6. About 422,169 shares traded. Abeona Therapeutics Inc. (NASDAQ:ABEO) has risen 151.02% since January 21, 2017 and is uptrending. It has outperformed by 134.32% the S&P500.
Meiji Yasuda Life Insurance Company increased Nextera Energy Inc (NEE) stake by 9.86% reported in 2017Q3 SEC filing. Meiji Yasuda Life Insurance Company acquired 2,800 shares as Nextera Energy Inc (NEE)’s stock rose 8.22%. The Meiji Yasuda Life Insurance Company holds 31,201 shares with $4.57 million value, up from 28,401 last quarter. Nextera Energy Inc now has $70.64 billion valuation. The stock decreased 0.41% or $0.62 during the last trading session, reaching $150.16. About 2.25 million shares traded or 26.87% up from the average. NextEra Energy, Inc. (NYSE:NEE) has risen 15.94% since January 21, 2017 and is uptrending. It has underperformed by 0.76% the S&P500.
Since August 3, 2017, it had 0 insider purchases, and 4 insider sales for $9.61 million activity. The insider Kelliher Joseph T sold 2,000 shares worth $300,000. $4.47M worth of NextEra Energy, Inc. (NYSE:NEE) was sold by Sieving Charles E. ROBO JAMES L sold $4.41 million worth of stock or 30,000 shares. The insider KETCHUM JOHN W sold $435,000.
Among 15 analysts covering Nextera Energy Inc. (NYSE:NEE), 13 have Buy rating, 0 Sell and 2 Hold. Therefore 87% are positive. Nextera Energy Inc. had 36 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, October 16 by Goldman Sachs. On Monday, July 31 the stock rating was maintained by RBC Capital Markets with “Buy”. The stock has “Hold” rating by Zacks on Monday, August 31. The stock has “Buy” rating by Deutsche Bank on Monday, January 30. The rating was upgraded by Robert W. Baird to “Outperform” on Friday, January 29. The rating was maintained by M Partners with “Buy” on Tuesday, August 11. The stock of NextEra Energy, Inc. (NYSE:NEE) has “Buy” rating given on Tuesday, January 2 by Guggenheim. Morgan Stanley maintained NextEra Energy, Inc. (NYSE:NEE) rating on Thursday, August 10. Morgan Stanley has “Overweight” rating and $167 target. The rating was maintained by JP Morgan on Thursday, October 12 with “Neutral”. Deutsche Bank maintained NextEra Energy, Inc. (NYSE:NEE) rating on Monday, October 5. Deutsche Bank has “Buy” rating and $112 target.
Investors sentiment decreased to 0.95 in Q3 2017. Its down 0.02, from 0.97 in 2017Q2. It dropped, as 38 investors sold NEE shares while 396 reduced holdings. 89 funds opened positions while 323 raised stakes. 344.40 million shares or 7.22% less from 371.19 million shares in 2017Q2 were reported. Clark Mgmt Group Incorporated accumulated 253,772 shares. Nomura Inc reported 26,249 shares or 0.01% of all its holdings. Old Second Natl Bank Of Aurora invested in 1,267 shares or 0.08% of the stock. Putnam Ltd Com, Massachusetts-based fund reported 616,772 shares. Sweden-based Livforsakringsbolaget Skandia Omsesidigt has invested 0.12% in NextEra Energy, Inc. (NYSE:NEE). Legg Mason Asset Mgmt (Japan) holds 1.67% of its portfolio in NextEra Energy, Inc. (NYSE:NEE) for 19,300 shares. Main Street Ltd Limited Liability Company invested in 1,478 shares. Cidel Asset Management invested in 164,154 shares. 27,410 were accumulated by Gateway Investment Advisers Lc. Scotia Capital invested 0.01% of its portfolio in NextEra Energy, Inc. (NYSE:NEE). Ing Groep Nv reported 32,233 shares. Inv Services Inc owns 0.13% invested in NextEra Energy, Inc. (NYSE:NEE) for 2,300 shares. Laurel Grove Capital Ltd Liability has 4,450 shares. Rodgers Brothers Inc holds 2,085 shares or 0.11% of its portfolio. Budros Ruhlin Roe owns 2,745 shares.
Meiji Yasuda Life Insurance Company decreased Goldman Sachs Group Inc (NYSE:GS) stake by 8,275 shares to 1,534 valued at $364,000 in 2017Q3. It also reduced Citigroup Inc (NYSE:C) stake by 7,960 shares and now owns 90,308 shares. Prudential Finl Inc (NYSE:PRU) was reduced too.
Among 10 analysts covering Abeona Therapeutics (NASDAQ:ABEO), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Abeona Therapeutics had 31 analyst reports since December 16, 2015 according to SRatingsIntel. As per Friday, January 6, the company rating was initiated by Jefferies. The firm has “Buy” rating given on Monday, September 25 by Cantor Fitzgerald. Citigroup initiated Abeona Therapeutics Inc. (NASDAQ:ABEO) rating on Tuesday, October 10. Citigroup has “Buy” rating and $32.0 target. The rating was maintained by Jefferies on Thursday, June 1 with “Buy”. The firm has “Buy” rating by Cantor Fitzgerald given on Friday, October 6. Jefferies maintained the shares of ABEO in report on Friday, September 22 with “Buy” rating. The rating was maintained by FBR Capital on Thursday, May 25 with “Buy”. The firm earned “Buy” rating on Thursday, January 4 by H.C. Wainwright. The firm has “Buy” rating by Cowen & Co given on Tuesday, August 8. Maxim Group maintained Abeona Therapeutics Inc. (NASDAQ:ABEO) rating on Tuesday, August 29. Maxim Group has “Buy” rating and $17.0 target.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma products for severe and life-threatening rare diseases. The company has market cap of $682.92 million. The companyÂ’s lead programs are ABO-101, an adeno-associated virus based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. It currently has negative earnings. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9 gene editing approach to gene therapy program for rare blood diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.